Katherine E. Francis
YOU?
Author Swipe
View article: Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial Open
SOLACE2 (ACTRN12618000686202) investigates whether 12-weeks of olaparib, or cyclophosphamide-olaparib priming, improves subsequent durvalumab-olaparib progression-free survival (PFS), and is superior to olaparib monotherapy without any pri…
View article: Under the radar—frequency, timing, duration, and trajectory of lower-grade adverse events in clinical trials of anti-cancer therapies
Under the radar—frequency, timing, duration, and trajectory of lower-grade adverse events in clinical trials of anti-cancer therapies Open
Importance The current methods to capture and report adverse events (AEs) in clinical trials were developed in the era of cytotoxic chemotherapy and typically focused on higher grade AEs which may lead to severe harms. However, current can…
View article: Management of Acute Coronary Syndromes in the Cardiology Department of the National Ignace Deen Teaching Hospital in Conakry
Management of Acute Coronary Syndromes in the Cardiology Department of the National Ignace Deen Teaching Hospital in Conakry Open
View article: Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer Open
Virtually all PSROC participants in the SOLO2/ENGOT-Ov21 experienced one or more AE whilst on placebo. Furthermore, study investigators attributed one quarter of AEs to be related to placebo therapy and dose alterations and treatment chang…
View article: Adverse Events in the Placebo Arm of Solo2/Engot-Ov21 Maintenance Trial of Olaparib in Recurrent Ovarian Cancer
Adverse Events in the Placebo Arm of Solo2/Engot-Ov21 Maintenance Trial of Olaparib in Recurrent Ovarian Cancer Open
View article: Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer Open
Background CA-125 alone is widely used to diagnose progressive disease (PD) in platinum-sensitive recurrent ovarian cancer (PSROC) on chemotherapy. However, there are increasing concerns regarding its accuracy. We assessed concordance betw…
View article: Utilisation of a Novel Test to Measure Severity and Treatment Efficacy of Posterior Blepharitis
Utilisation of a Novel Test to Measure Severity and Treatment Efficacy of Posterior Blepharitis Open
Background . This study evaluated the effectiveness of managing posterior blepharitis (PB) using a novel Posterior Blepharitis Management Protocol (PBMP). Design . Prospective, consecutive case series with 100% followup to one month. Parti…